Drug Profile
Borneol/edaravone - Simcere
Alternative Names: Compound edaravone; Edaravone combination; Edaravone Dexborneol; Edaravone/borneol; Sanbaxin®; Sanbexin; SIM 071201Latest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator NeuroDawn; Simcere Pharmaceutical Group
- Developer Simcere Pharmaceutical Group
- Class Antidementias; Heterocyclic bicyclo compounds; Neuroprotectants; Pyrazolones; Small molecules; Terpenes; Vascular disorder therapies
- Mechanism of Action Antioxidants; Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Stroke
- Phase II Cerebral haemorrhage
- No development reported Cerebrovascular disorders
Most Recent Events
- 18 Mar 2024 Simcere Pharmaceutical plans phase-II trial for Cognition disorders (In adults, In the elderly) in China (Sublingual, Tablet) in March 2024 (NCT06315231),
- 03 Jul 2023 Phase-II clinical trials in Cerebral haemorrhage (Combination therapy, In adults, In the elderly) in China (Injection) (NCT05953103)
- 01 Jun 2023 Simcere Pharmaceutical Group plans a phase III EARLYS trial for Stroke in China (Parenteral, Injection) (NCT05885919)